Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients

Table 5 HR estimates of overall and breast cancer-specific survival by TP53 R72P, in p53 negative and positive tumors (multivariate models)

TP53R72P	HR	Lower and upper limit 95% CI		P value
Overall survival
p53 negative tumors
GC	1.11	0.80	1.52	0.54
CC	1.63	0.97	2.74	0.06
p53 positive tumors
GC	0.82	0.53	1.27	0.37
CC	0.86	0.34	2.18	0.75
Breast cancer-specific survival
p53 negative tumors
GC	0.97	0.68	1.37	0.85
CC	1.79	1.05	3.05	0.03
p53 positive tumors
GC	0.90	0.57	1.42	0.65
CC	1.00	0.39	2.55	1.00
*MDM2 SNP309*	HR	Lower and upper limit 95% CI		P value
Overall survival
p53 negative tumors
TG	0.84	0.60	1.17	0.30
GG	1.28	0.85	1.94	0.24
p53 positive tumors
TG	0.78	0.49	1.24	0.30
GG	0.78	0.41	1.48	0.45
Breast cancer-specific survival
p53 negative tumors
TG	0.92	0.64	1.31	0.63
GG	1.41	0.90	2.19	0.13
p53 positive tumors
TG	0.76	0.47	1.23	0.27
GG	0.69	0.35	1.39	0.30

Pooled analyses for studies with p53 information (ABCS and HEBCS); HRs of heterozygous and homozygous rare allele groups have been calculated by comparison to the reference categories of the homozygous common allele: TP53 R72P = GG, and MDM2 SNP309 = TT; analyses have been adjusted for study, age, stage, grade and ER.

ISSN: 1465-542X